U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Osteosarcoma

MedGen UID:
1648182
•Concept ID:
C4684870
•
Neoplastic Process

Definition

Osteosarcoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Osteosarcoma

Professional guidelines

PubMed

The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies.
Kovac M, Ameline B, Ribi S, Kovacova M, Cross W, Barenboim M, Witt O, Bielack S, Krieg A, Hartmann W, Nathrath M, Baumhoer D
J Pathol 2021 Aug;254(5):556-566. Epub 2021 May 25 doi: 10.1002/path.5699. PMID: 33963544Free PMC Article
Gemcitabine for the treatment of patients with osteosarcoma.
Wei MY, Zhuang YF, Wang WM
Asian Pac J Cancer Prev 2014;15(17):7159-62. doi: 10.7314/apjcp.2014.15.17.7159. PMID: 25227807
Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide.
Rodríguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, Rao BN, Pratt CB
J Pediatr Hematol Oncol 2002 May;24(4):250-5. doi: 10.1097/00043426-200205000-00006. PMID: 11972091

Recent clinical studies

Etiology

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
Xie L, Liang X, Xu J, Sun X, Liu K, Sun K, Li Y, Tang X, Li X, Zhan X, Niu X, Guo W
BMC Cancer 2023 Sep 15;23(1):868. doi: 10.1186/s12885-023-11390-4. PMID: 37715133Free PMC Article
Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Sugiyama M, Arakawa A, Shirakawa N, Tao K, Tanimura K, Nakajima M, Watanabe Y, Kumamoto T, Maniwa J, Yoneda A, Iwata S, Kobayashi E, Kawai A, Ogawa C
Pediatr Blood Cancer 2023 Jul;70(7):e30360. Epub 2023 Apr 19 doi: 10.1002/pbc.30360. PMID: 37073613
Circular RNA circFIRRE drives osteosarcoma progression and metastasis through tumorigenic-angiogenic coupling.
Yu L, Zhu H, Wang Z, Huang J, Zhu Y, Fan G, Wang Y, Chen X, Zhou G
Mol Cancer 2022 Aug 19;21(1):167. doi: 10.1186/s12943-022-01624-7. PMID: 35986280Free PMC Article
Sorafenib in patients with progressed and refractory bone tumors.
Raciborska A, Bilska K
Med Oncol 2018 Aug 16;35(10):126. doi: 10.1007/s12032-018-1180-x. PMID: 30116912Free PMC Article
Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide.
Rodríguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, Rao BN, Pratt CB
J Pediatr Hematol Oncol 2002 May;24(4):250-5. doi: 10.1097/00043426-200205000-00006. PMID: 11972091

Diagnosis

Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
Kinnaman MD, Zaccaria S, Makohon-Moore A, Arnold B, Levine MF, Gundem G, Arango Ossa JE, Glodzik D, Rodríguez-Sánchez MI, Bouvier N, Li S, Stockfisch E, Dunigan M, Cobbs C, Bhanot UK, You D, Mullen K, Melchor JP, Ortiz MV, O'Donohue TJ, Slotkin EK, Wexler LH, Dela Cruz FS, Hameed MR, Glade Bender JL, Tap WD, Meyers PA, Papaemmanuil E, Kung AL, Iacobuzio-Donahue CA
Cancer Res 2023 Nov 15;83(22):3796-3812. doi: 10.1158/0008-5472.CAN-23-0385. PMID: 37812025Free PMC Article
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza C, Bastoni S, Scanagatta P
Expert Rev Anticancer Ther 2020 May;20(5):415-428. Epub 2020 May 7 doi: 10.1080/14737140.2020.1760848. PMID: 32379504
Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, Mao M, Zuo D, Zhou Z, Wang C, Fu Z, Wang Z, Duan Z, Hua Y, Cai Z
Int J Cancer 2019 Aug 15;145(4):979-993. Epub 2019 Feb 15 doi: 10.1002/ijc.32180. PMID: 30719715
Sorafenib in patients with progressed and refractory bone tumors.
Raciborska A, Bilska K
Med Oncol 2018 Aug 16;35(10):126. doi: 10.1007/s12032-018-1180-x. PMID: 30116912Free PMC Article
Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC
Cancer 2008 Jul 15;113(2):419-25. doi: 10.1002/cncr.23586. PMID: 18484657

Therapy

Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Sugiyama M, Arakawa A, Shirakawa N, Tao K, Tanimura K, Nakajima M, Watanabe Y, Kumamoto T, Maniwa J, Yoneda A, Iwata S, Kobayashi E, Kawai A, Ogawa C
Pediatr Blood Cancer 2023 Jul;70(7):e30360. Epub 2023 Apr 19 doi: 10.1002/pbc.30360. PMID: 37073613
The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.
Kiany S, Harrison D, Gordon N
Adv Exp Med Biol 2020;1257:75-83. doi: 10.1007/978-3-030-43032-0_7. PMID: 32483732
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza C, Bastoni S, Scanagatta P
Expert Rev Anticancer Ther 2020 May;20(5):415-428. Epub 2020 May 7 doi: 10.1080/14737140.2020.1760848. PMID: 32379504
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Xiao X, Wang W, Wang Z
Paediatr Drugs 2014 Dec;16(6):503-12. doi: 10.1007/s40272-014-0095-z. PMID: 25392156
Gemcitabine for the treatment of patients with osteosarcoma.
Wei MY, Zhuang YF, Wang WM
Asian Pac J Cancer Prev 2014;15(17):7159-62. doi: 10.7314/apjcp.2014.15.17.7159. PMID: 25227807

Prognosis

Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Sugiyama M, Arakawa A, Shirakawa N, Tao K, Tanimura K, Nakajima M, Watanabe Y, Kumamoto T, Maniwa J, Yoneda A, Iwata S, Kobayashi E, Kawai A, Ogawa C
Pediatr Blood Cancer 2023 Jul;70(7):e30360. Epub 2023 Apr 19 doi: 10.1002/pbc.30360. PMID: 37073613
Circular RNA circFIRRE drives osteosarcoma progression and metastasis through tumorigenic-angiogenic coupling.
Yu L, Zhu H, Wang Z, Huang J, Zhu Y, Fan G, Wang Y, Chen X, Zhou G
Mol Cancer 2022 Aug 19;21(1):167. doi: 10.1186/s12943-022-01624-7. PMID: 35986280Free PMC Article
The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.
Kiany S, Harrison D, Gordon N
Adv Exp Med Biol 2020;1257:75-83. doi: 10.1007/978-3-030-43032-0_7. PMID: 32483732
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza C, Bastoni S, Scanagatta P
Expert Rev Anticancer Ther 2020 May;20(5):415-428. Epub 2020 May 7 doi: 10.1080/14737140.2020.1760848. PMID: 32379504
Gemcitabine for the treatment of patients with osteosarcoma.
Wei MY, Zhuang YF, Wang WM
Asian Pac J Cancer Prev 2014;15(17):7159-62. doi: 10.7314/apjcp.2014.15.17.7159. PMID: 25227807

Clinical prediction guides

Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
Kinnaman MD, Zaccaria S, Makohon-Moore A, Arnold B, Levine MF, Gundem G, Arango Ossa JE, Glodzik D, Rodríguez-Sánchez MI, Bouvier N, Li S, Stockfisch E, Dunigan M, Cobbs C, Bhanot UK, You D, Mullen K, Melchor JP, Ortiz MV, O'Donohue TJ, Slotkin EK, Wexler LH, Dela Cruz FS, Hameed MR, Glade Bender JL, Tap WD, Meyers PA, Papaemmanuil E, Kung AL, Iacobuzio-Donahue CA
Cancer Res 2023 Nov 15;83(22):3796-3812. doi: 10.1158/0008-5472.CAN-23-0385. PMID: 37812025Free PMC Article
Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
Xie L, Liang X, Xu J, Sun X, Liu K, Sun K, Li Y, Tang X, Li X, Zhan X, Niu X, Guo W
BMC Cancer 2023 Sep 15;23(1):868. doi: 10.1186/s12885-023-11390-4. PMID: 37715133Free PMC Article
Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Sugiyama M, Arakawa A, Shirakawa N, Tao K, Tanimura K, Nakajima M, Watanabe Y, Kumamoto T, Maniwa J, Yoneda A, Iwata S, Kobayashi E, Kawai A, Ogawa C
Pediatr Blood Cancer 2023 Jul;70(7):e30360. Epub 2023 Apr 19 doi: 10.1002/pbc.30360. PMID: 37073613
MicroRNA-519d-3p antagonizes osteosarcoma resistance against cisplatin by targeting PD-L1.
Wang J, Zhang Z, Qiu C, Wang J
Mol Carcinog 2022 Mar;61(3):322-333. Epub 2021 Nov 15 doi: 10.1002/mc.23370. PMID: 34780678
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza C, Bastoni S, Scanagatta P
Expert Rev Anticancer Ther 2020 May;20(5):415-428. Epub 2020 May 7 doi: 10.1080/14737140.2020.1760848. PMID: 32379504

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...